Titan Pharma (India ) Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 10-12-2024
- Paid Up Capital ₹ 0.38 M
as on 10-12-2024
- Company Age 23 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 7.09 Cr
as on 10-12-2024
- Revenue 3.62%
(FY 2022)
- Profit 13.22%
(FY 2022)
- Ebitda 9.57%
(FY 2022)
- Net Worth 9.81%
(FY 2022)
- Total Assets 9.18%
(FY 2022)
About Titan Pharma (India )
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.38 M.
The company has closed loans amounting to ₹7.09 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Piyush Shah and Deepak Shah serve as directors at the Company.
- CIN/LLPIN
U24234MH2001PTC133316
- Company No.
133316
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Sep 2001
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Titan Pharma (India )?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Piyush Shah  | Director | 09-Oct-2001 | Current |
| Deepak Shah | Director | 09-Oct-2001 | Current |
Financial Performance of Titan Pharma (India ).
Titan Pharma (India ) Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 3.62% increase. The company also saw a substantial improvement in profitability, with a 13.22% increase in profit. The company's net worth moved up by a moderate rise of 9.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Titan Pharma (India )?
Unlock access to Titan Pharma (India )'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Titan Laboratories Private LimitedActive 20 years 6 monthsPiyush Shah and Deepak Shah are mutual person
Titan Pharmaplus Private LimitedActive 2 years 9 monthsPiyush Shah and Deepak Shah are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Union Bank Of India Creation Date: 05 Aug 2005 | ₹6.74 Cr | Satisfied |
Union Bank Of India Creation Date: 31 May 2004 | ₹1.50 M | Satisfied |
Union Bank Of India Creation Date: 02 May 2002 | ₹1.00 M | Satisfied |
How Many Employees Work at Titan Pharma (India )?
Unlock and access historical data on people associated with Titan Pharma (India ), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Titan Pharma (India ), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Titan Pharma (India )'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
